[Skip to Navigation]
Sign In
October 1, 2020

Incorrect Supplement Version

JAMA Oncol. 2020;6(11):1815. doi:10.1001/jamaoncol.2020.5538

The article “Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial,”1 published in the May issue of JAMA Oncology, included an incorrect version of online Supplement 1. The correct version has been uploaded, and the Supplement is now correct online.

Rizvi  NA, Cho  BC, Reinmuth  N,  et al; MYSTIC Investigators.  Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial.   JAMA Oncol. 2020;6(5):661-674. doi:10.1001/jamaoncol.2020.0237PubMedGoogle ScholarCrossref